HEK293 Cell Line for rAAV Manufacturing
New study reports two-fold improvement in full-to-empty rAAV ratio versus commercial HEK293 line
Clinical Scorecard: HEK293 Cell Line for rAAV Manufacturing
At a Glance
Category Detail
Condition Gene therapy development Key Mechanisms Recombinant adeno-associated virus (rAAV) production Target Population Patients requiring gene therapies Care Setting Biotechnology and pharmaceutical manufacturing
Key Highlights
NBX1P01 produced a two-fold higher full-to-empty rAAV capsid ratio compared to a leading commercial HEK293 cell line. Demonstrated genomic stability over 55 population doubling levels with lower genetic heterogeneity. Confirmed more than 70% intact rAAV genomes with minimal encapsidated contaminating DNA. Consistent performance across production volumes from 10 mL to 1.5 L. Supported multiple rAAV serotypes and clinically relevant transgene sizes. Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Broader patient populations as gene therapy programs expand beyond rare diseases.
Quality and consistency in rAAV production are essential for effective gene therapies.
Clinical Best Practices
Utilize stable and adaptable cell lines for rAAV production. Ensure high full-to-empty capsid ratios for quality assurance. Monitor genomic stability to reduce variability in manufacturing. References
